NH SB606

Requires health insurance plans issued, amended, or renewed on or after January 1, 2027 to cover biomarker testing for diagnosis, treatment, management, or ongoing monitoring of diseases when tests demonstrate clinical utility

Defines biomarkers as measurable characteristics including gene mutations, protein expression, and gene-drug interactions that indicate biological or pathogenic processes or responses to therapeutic interventions

Mandates coverage when supported by FDA-approved test indications, FDA-approved drug requirements, CMS coverage determinations, or nationally recognized clinical practice guidelines

Establishes prior authorization timelines of 14 days for non-urgent requests and 72 hours for urgent requests, and requires insurers to minimize disruptions such as multiple biopsies

Extends the same biomarker testing coverage requirements to the state Medicaid plan and requires the Department of Health and Human Services to submit any necessary state plan amendments to CMS